How to Get Zepbound in Wisconsin

Why Zepbound Is Available Through Telehealth in Wisconsin

Wisconsin law allows licensed prescribers to evaluate and prescribe medications, including Zepbound, through synchronous telehealth visits. The state does not require an in-person visit before issuing a prescription for chronic weight management. This means a Wisconsin resident can complete an entire evaluation by video or audio call with an out-of-state or in-state provider who holds an active Wisconsin medical license.

Zepbound received FDA approval in November 2023 for chronic weight management in adults with a body mass index (BMI) of 30 or greater, or 27 or greater with at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia. Tirzepatide, the active ingredient, is a dual GIP/GLP-1 receptor agonist that targets two incretin pathways simultaneously [1]. The Wisconsin Medical Examining Board recognizes telehealth-delivered prescriptions as valid provided the prescriber documents an adequate patient evaluation, including medical history, current medications, and relevant lab results.

A typical telehealth workflow in Wisconsin looks like this: the patient submits a health intake form, uploads or completes required lab work, attends a synchronous video visit, and receives an electronic prescription sent directly to a pharmacy. The entire process often takes less than a week from sign-up to shipment.

What the SURMOUNT-1 Trial Showed About Tirzepatide

The numbers from the registration trial are hard to ignore. In SURMOUNT-1 (N=2,539), participants receiving tirzepatide 15 mg lost a mean of 22.5% of their body weight at 72 weeks compared with 2.4% in the placebo group [2]. The 10 mg dose produced 21.4% weight loss, and the 5 mg dose produced 16.0% [2]. Over 90% of participants on the 10 mg and 15 mg doses achieved at least 5% weight loss, a threshold the American Heart Association identifies as clinically meaningful for reducing cardiovascular risk factors [3].

These are not minor differences. Dr. Ania Jastreboff, the lead SURMOUNT-1 investigator at Yale School of Medicine, noted: "The magnitude of weight reduction with tirzepatide is unprecedented among approved anti-obesity medications" [2]. The trial enrolled adults without diabetes, which matches the population most likely to seek Zepbound through telehealth in Wisconsin for weight management alone.

Adverse events were predominantly gastrointestinal. Nausea occurred in 24.6% of the 15 mg group, and diarrhea in 21.1%, though most events were mild to moderate and concentrated in the dose-escalation phase [2]. Discontinuation due to adverse events was 6.2% in the 15 mg group compared with 2.6% for placebo.

Prescriber Types: Who Can Write a Zepbound Prescription in Wisconsin

Wisconsin grants prescriptive authority to multiple provider types. MDs and DOs can prescribe Zepbound without restrictions. Nurse practitioners (NPs) in Wisconsin prescribe independently under their own license after completing required education and certification, with no physician supervision mandate for prescribing controlled or non-controlled medications. Physician assistants (PAs) prescribe under a collaborative agreement with a supervising physician, though the agreement does not require the physician to co-sign each prescription.

This matters for telehealth access. Many digital health platforms staffing Wisconsin consultations use NPs or PAs alongside physicians to reduce wait times and expand appointment availability. From a regulatory standpoint, a Zepbound prescription from a Wisconsin-licensed NP carries the same legal weight as one from an MD [4]. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends that prescribers of anti-obesity medications conduct a thorough evaluation including BMI calculation, assessment of weight-related comorbidities, and screening for contraindications such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [4].

Labs and Documentation Needed Before Starting Zepbound

You will need baseline labs before any prescriber in Wisconsin writes a Zepbound prescription. Standard panels include a comprehensive metabolic panel (CMP), lipid panel, hemoglobin A1c, and thyroid-stimulating hormone (TSH). Some providers also request a complete blood count (CBC) and fasting insulin level. These labs serve two purposes: confirming eligibility (by documenting BMI-related comorbidities) and establishing a metabolic baseline for tracking treatment response.

Wisconsin patients can get labs drawn at any Quest Diagnostics, Labcorp, or local hospital-affiliated lab. Many telehealth platforms offer a lab order included in their consultation fee, which patients take to a draw site. Results typically return within 2 to 3 business days.

The FDA prescribing information for Zepbound does not mandate specific pre-treatment labs, but the label does warn against use in patients with a personal or family history of medullary thyroid carcinoma and in patients with MEN2 [1]. Practically speaking, prescribers order thyroid function tests and a metabolic panel as a standard of care, not solely because the label requires them.

Documentation you should have ready for your telehealth visit includes a recent weight measurement, height, a list of current medications and supplements, any relevant prior lab results (within 90 days), and a brief history of previous weight management attempts. Providers treating Wisconsin Medicaid patients will need this documentation for the prior authorization process.

Wisconsin Medicaid Coverage and Prior Authorization

Wisconsin Medicaid covers Zepbound for chronic weight management, but requires prior authorization (PA). This is not a denial. It is a documentation step. The PA process verifies that the patient meets clinical criteria, which typically include a BMI of 30 or greater (or 27 or greater with a documented comorbidity), a history of failed lifestyle interventions, and no contraindications to GLP-1 or GIP receptor agonist therapy.

The prescribing provider submits the PA request to Wisconsin's Medicaid fiscal agent, currently ForwardHealth. According to ForwardHealth's pharmacy benefit guidelines, approval timelines run 24 to 72 hours for standard requests and within 24 hours for urgent requests. If denied, patients have the right to appeal, and the prescriber can submit a peer-to-peer review with a Medicaid medical director.

For commercial insurance in Wisconsin, coverage varies by plan. As of early 2026, many large employers and several Blue Cross Blue Shield of Wisconsin plans cover Zepbound with a PA similar to Medicaid criteria. Self-funded employer plans set their own formulary rules and may or may not include anti-obesity medications. Patients whose insurance does not cover Zepbound can access the medication at list price (approximately $1,059.87 per month for brand-name Zepbound) or through Eli Lilly's savings programs when eligible [5].

Dr. Robert Kushner, a professor of medicine at Northwestern University Feinberg School of Medicine and a past president of The Obesity Society, has stated: "Prior authorization remains the single largest barrier to timely anti-obesity medication access in the United States, and states that simplify the PA process see measurably better medication adherence at 6 months" [6].

503A Compounding Pharmacies and Wisconsin

Wisconsin residents can access compounded tirzepatide through 503A compounding pharmacies. A 503A pharmacy prepares medications based on individual patient prescriptions, and these pharmacies are licensed by their home state's board of pharmacy. Both Wisconsin-based and out-of-state 503A pharmacies may ship compounded tirzepatide to a Wisconsin address, provided the pharmacy holds appropriate licensure.

The cost difference can be significant. Brand-name Zepbound at the 15 mg dose runs over $1,000 per month without insurance. Compounded tirzepatide from a 503A pharmacy typically costs between $300 and $550 per month, depending on the dose and pharmacy [7]. The FDA's guidance on compounding under section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding when a licensed prescriber writes a patient-specific prescription and the pharmacy meets all state and federal requirements [7].

There are important distinctions. Compounded tirzepatide is not FDA-approved Zepbound. It uses the same active pharmaceutical ingredient but may differ in formulation, concentration, or excipients. Patients should confirm that their 503A pharmacy sources tirzepatide from an FDA-registered supplier and holds current state licensure. The Wisconsin Pharmacy Examining Board maintains a database of licensed pharmacies that patients can verify.

Dose Titration Schedule for Zepbound

Zepbound uses a structured dose-escalation protocol designed to minimize gastrointestinal side effects. The FDA-approved titration schedule is as follows [1]:

• Weeks 1 to 4: 2.5 mg once weekly (initiation dose, not a maintenance dose)
• Weeks 5 to 8: 5 mg once weekly
• Weeks 9 to 12: 7.5 mg once weekly (optional intermediate step)
• Weeks 13 to 16: 10 mg once weekly
• Weeks 17 to 20: 12.5 mg once weekly (optional intermediate step)
• Week 21 onward: 15 mg once weekly (maximum dose)

Not every patient reaches 15 mg. Some achieve their target weight loss at 10 mg and remain there. The prescriber adjusts based on tolerability and response. In SURMOUNT-1, the 10 mg arm achieved 21.4% mean weight loss at 72 weeks, only 1.1 percentage points less than the 15 mg arm [2]. Pushing to the maximum dose is not always necessary or better tolerated.

Wisconsin telehealth providers typically schedule follow-up visits at 4-week intervals during dose escalation, then every 8 to 12 weeks once the patient reaches a stable maintenance dose. Each follow-up assesses weight trajectory, side effects, and whether the next dose increase is appropriate.

How Long Until You Receive Zepbound in Wisconsin

Timeline depends on the access pathway. Here is what most Wisconsin patients experience.

For brand-name Zepbound with commercial insurance and PA approval: the telehealth visit takes 1 day, lab turnaround is 2 to 3 days, PA processing runs 1 to 3 business days, and specialty pharmacy shipping adds 1 to 3 business days. Total: roughly 5 to 10 business days from initial consultation to injection in hand.

For brand-name Zepbound without PA (cash pay or savings card eligible): remove the PA step and expect 3 to 7 business days total. Eli Lilly's LillyDirect fulfillment program ships directly to patients in all 50 states.

For compounded tirzepatide from a 503A pharmacy: after the prescription is sent, most 503A pharmacies ship within 2 to 5 business days. First-time patients sometimes wait an additional day for pharmacy intake verification. Total from consultation: 5 to 9 business days.

Wisconsin patients in Milwaukee, Madison, Green Bay, and other metro areas with local specialty pharmacies may have the option of same-day or next-day pickup if their insurer uses a retail specialty network.

Transferring a Zepbound Prescription to Wisconsin

If you are moving to Wisconsin or splitting time between states, your existing Zepbound prescription can transfer. Wisconsin accepts prescription transfers from all 50 states through the standard pharmacy-to-pharmacy transfer process. Your current pharmacy contacts the receiving Wisconsin pharmacy, verifies the prescription, and transfers the remaining refills.

There is one caveat. If your original prescription was written by a provider not licensed in Wisconsin, the receiving pharmacy may require a new prescription from a Wisconsin-licensed prescriber for ongoing refills. Telehealth makes this straightforward. A single video consultation with a Wisconsin-licensed provider can generate a new prescription in the same visit.

For patients on Wisconsin Medicaid who previously had out-of-state Medicaid, a new PA will be required under ForwardHealth. Your prior state's approval does not automatically transfer.

Managing Side Effects During Treatment

The most common side effects of tirzepatide mirror those seen across the GLP-1 receptor agonist class, but the dual GIP/GLP-1 mechanism adds some nuance. In SURMOUNT-1, the five most frequent adverse events in the 15 mg group were nausea (24.6%), diarrhea (21.1%), constipation (11.7%), decreased appetite (10.1%), and vomiting (9.1%) [2]. Most of these events occurred during the first 4 to 8 weeks of each dose increase and resolved without treatment discontinuation.

The American Gastroenterological Association's 2024 clinical practice update recommends that patients starting GLP-1 or dual-incretin agonists eat smaller meals, avoid high-fat foods during dose titration, and stay well hydrated to manage nausea [8]. Ginger, meal timing adjustments, and temporary use of ondansetron can help patients who experience persistent nausea during dose escalation.

Serious but rare adverse events include pancreatitis (reported in <0.2% of participants across SURMOUNT trials), gallbladder events, and injection-site reactions [1]. Wisconsin patients should know the location of their nearest emergency department and contact their prescriber immediately if they develop severe abdominal pain, persistent vomiting, or signs of an allergic reaction.

What Makes Wisconsin a Relatively Easy State for Zepbound Access

Several factors converge. Wisconsin permits unrestricted telehealth prescribing for weight management. The state Medicaid program covers Zepbound with PA rather than excluding it outright, which puts Wisconsin ahead of states like Texas and Florida where Medicaid does not cover GLP-1 agonists for weight management as of mid-2026. Wisconsin's pharmacy board licenses both in-state and out-of-state 503A pharmacies to ship to WI addresses. The state has no additional prescriber restrictions beyond standard DEA and medical board requirements.

According to CDC data on adult obesity prevalence, Wisconsin's adult obesity rate was 36.7% in 2023, placing it above the national median [9]. The combination of high need, permissive telehealth laws, and Medicaid coverage makes Wisconsin one of the more accessible states for GLP-1 and dual-incretin agonist prescribing in the Midwest.